Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy
Reminder: Company to Host Investor Call
"We're very happy to have appointed Ian to this key role,"
Prior to joining Jaguar, Wendt was at Gilead Sciences in a variety of field leadership and marketing roles in the HIV and hepatitis C therapeutic areas. Most recently, he led strategy and tactical development for a national team focused on policy and protocol development within key HIV treatment and prevention accounts, capacity building, and direct patient education. Wendt was also responsible for Gilead's efforts to increase hepatitis C virus screening and treatment among non-specialist health care practitioners in support of Gilead's market development efforts for a
"I firmly believe in Jaguar's mission to continue driving commercial growth of Mytesi (crofelemer) for its current approved indication, and to develop and commercialize a broad-based suite of follow-on indications for patient populations in need around the world," Wendt commented. "I am excited to have the opportunity to contribute to the growth and expansion of this innovative company in the months and years to come."
Dial-In Instructions for Conference Call
When: November 14, 2019 at
Dial-in (US Toll Free): 800-289-0438
Dial-in (International): 323-794-2423
Conference ID number: 3702255
Live webcast on the investor relations section of Jaguar's website (click here)
Dial-in (US Toll Free): 844-512-2921
Dial-in (International): 412-317-6671
Replay Pin Number: 3702255
Replay of the webcast on the investor relations section of Jaguar's website (click here)
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the belief that Wendt's broad commercial leadership expertise in the pharmaceutical industry, and in the HIV sector, will play a significant role as the Company continues to focus on enhancing patient and market access to Mytesi (crofelemer) for its current FDA-approved indication, the expectation that Wendt will play a pivotal role in driving commercial efforts in the cancer sector if crofelemer receives approval for CTD, and the expectation that Jaguar will host a conference call on